A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 998
- 试验地点
- 66
- 主要终点
- Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment
研究概览
简要总结
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
- •Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
排除标准
- •Having received MF treatment in a clinical trial setting.
结局指标
主要结局
Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment
时间窗: Up to Week 156
Time from diagnosis of MF to initial treatment.
Duration of Second Treatment
时间窗: Up to Week 156
Duration of second treatment.
Duration of Initial Treatment
时间窗: Up to Week 156
Duration of initial treatment.
Duration of Subsequent Treatments
时间窗: Up to Week 156
Duration of subsequent treatments.
次要结局
未报告次要终点